U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216014) titled 'Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety' on Sept. 28.
Brief Summary: Patients diagnosed with moderate to severe CD or UC who had received at least 8 weeks of infliximab treatment by the end of the study period were selected. After obtaining informed consent, treatment with infliximab-based drugs was initiated. Basic patient information and medical history were collected. The treatment process was followed, and the drug treatment plan was adjusted based on physician experience. Follow-up and disease assessments were conducted at 0, 4, 8, 16, 24, 48, and 54 weeks. At corresponding follow-...